← Back to Clinical Trials
Recruiting NCT04218318

Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Hemolytic Disease of Newborn
Sponsor Ministry of Health, Saudi Arabia
Study Type INTERVENTIONAL
Phase N/A
Enrollment 84
Sex ALL
Min Age 1 Hour
Max Age 14 Days
Start Date 2019-10-01
Completion 2026-10-31
Interventions
phototherapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

We hypothesized that adopting a lower rather than a higher threshold for phototherapy discontinuation will be associated with reduced rates of rebound hyperbilirubinemia in term and late preterm neonates with hemolytic disease of newborn. Objectives: The investigators aimed to compare the safety of implementing low-threshold, compared to high- threshold, of TSB for phototherapy interruption in term and late preterm neonates with hemolytic disease of newborn.

Eligibility Criteria

Inclusion Criteria: Healthy term and late-preterm neonates more than or equal 35 weeks gestation with hemolytic disease of newborn will be included. Enrolled infants should have evidence of hemolysis as defined by any of the following criteria: 1. positive DAT and blood group iso-immunization (ABO / RH incompatibility);and /or 2. HGB decline by 2g/dl within 24hour. Exclusion Criteria: * Major congenital abnormalities, * Surgical problems, * Direct hyperbilirubinemia * Sepsis

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}